AbbVie to Present at the Jefferies 2016 London Healthcare Conference
Get Alerts ABBV Hot Sheet
Join SI Premium – FREE
NORTH CHICAGO, Ill., Nov. 1, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2016 London Healthcare Conference on Thursday, November 17, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 3:20 a.m. Central time.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An archived edition of the session will be available later that day.
About AbbVie AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
Logo: http://photos.prnewswire.com/prnh/20160706/386913LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abbvie-to-present-at-the-jefferies-2016-london-healthcare-conference-300353291.html
SOURCE AbbVie
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbbVie seeks EMA approval for Skyrizi subcutaneous use in Crohn's
- SWE90 Offers Fiduciary Advisory and Brokerage Services in California
- Carhartt Data Breach: Ademi LLP Investigates Claims for Damages
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share